SRI-37330

SRI-37330 (CAS No.: 2322245-42-9) is an orally bioavailable small-molecule inhibitor of thioredoxin-interacting protein (TXNIP), a key regulator of cellular redox balance and metabolic homeostasis, widely studied in the context of metabolic disorders and endocrine signaling. By suppressing TXNIP expression at both mRNA and protein levels in cellular systems, SRI-37330 modulates downstream pathways involved in glucose and lipid metabolism, including the regulation of pancreatic α-cell function and glucagon secretion, as well as hepatic gluconeogenesis. This dual action results in reduced hepatic glucose output and improvement of lipid handling, contributing to attenuation of hepatic steatosis. In vitro studies demonstrate activity in the low micromolar range, along with the ability to inhibit inflammatory cell death processes such as pyroptosis under specific experimental conditions. In vivo, SRI-37330 has been shown to lower blood glucose, glucagon, and triglyceride levels in multiple murine models of diabetes and metabolic dysfunction, supporting its relevance in studying insulin resistance, glucagon signaling pathways, and liver metabolism. As a pharmacological probe, it is broadly applicable in cell-based assays and animal models investigating type 2 diabetes, metabolic syndrome, and associated inflammatory mechanisms, with experimental concentrations or dosing regimens varying according to specific study designs and therapeutic hypotheses.